LGVN: Approaching an Exciting Inflection Point
Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and...
142 Views
LGVN: Exciting Pipeline Moving Forward and Boosting Price Target
Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and...
179 Views
LGVN: Company Adds to Heart Treatment Technologies
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
225 Views
LGVN: Treatment Approved for Phase 2 Trial
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
252 Views
LGVN: Enrollment Complete for Pivotal Trial
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...
229 Views